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Spironolactone (SPR) is a steroidal drug administered as a potassium-sparing diuretic for high blood 
pressure treatment. The drug shows incomplete gastrointestinal absorption due to its poor aqueous 
solubility. The physicochemical properties of SPR in crystal forms I and II suggest that differences in their 
aqueous solubility may lead to a lack of bioequivalence between solid-state formulations. In this study, 
SPR polymorphs in five batches of active pharmaceutical ingredients (APIs) from three manufacturers 
were characterized using powder X-ray diffraction, infrared spectroscopy, thermal analysis, and solubility 
measurements. SPR tablets (50 mg) were manufactured in our laboratory using API in pure form II, and 
API in form II contaminated with form I, which was found in a commercial batch. Physicochemical quality 
evaluations of the manufactured tablets, along with five SPR tablets marketed in Brazil, were performed, 
and results indicated differences in their dissolution profiles. In the manufactured tablets, differences were 
associated with the increased solubility of API in form II contaminated with form I compared to API in 
pure form II. In the marketed SPR tablets, the formulation composition demonstrated an important role in 
the dissolution rate of the drug, leading to lack of pharmaceutical equivalence among the drug products.
Uniterms: Spironolactone/dissolution profile. Spironolactone/pharmaceutical equivalence. 
Spironolactone/solubility. Spironolactone/polymorphism. Drugs/quality assessment.
INTRODUCTION
Spironolactone [SPR; 7α-acetylthio-17α-hydroxyl-
3-oxopregn-4-ene-21-carboxylic acid γ-lactone], 
classified as a potassium-sparing diuretic, is a steroidal 
drug administered for the treatment of various disorders 
including high blood pressure, refractory edema in 
congestive heart failure, ascites, and essential hypertension 
(Giron, 1995; Soliman et al., 1997; Ismail, Chandrasekhar, 
Gunasekaran et al., 2014; Rahul, Patel, Bapna, 2014; 
Pisegna, Gilson, Butler, 2014; Zhang et al., 2014). The 
drug has also been administered for the treatment and 
prevention of hypokalemia (Rahul, Patel, Bapna, 2014), 
and reportedly has anti-androgenic activity, acting 
as a competitor for 5α-dihydrotestosterone receptors 
(Ram, Dave, Joshi, 2012). According to its chemical 
structure (Figure 1), spironolactone is a lipophilic drug 
(log Kow = 2.78) with two ionizable groups (pKa = -4.9 and 
18.0, respectively). It has been shown to be a crystalline 
powder, practically insoluble in water; however, it is 
soluble in alcohol and ethyl acetate, very soluble in 
chloroform and benzene, and slightly soluble in methanol 
(Brandão et al., 2008; Zhang et al., 2014).
The gastrointestinal absorption of SPR is variable 
and incomplete due to its poor water solubility (Agafonov 
et al., 1991; Liebenberg et al., 2003). It is classified 
as a class II drug according to the Biopharmaceutics 
Classification System (BCS) (Takahashi et al., 2012), 
which may be related to different arrays in the solid 
state due to its molecular flexibility (Salole, Al-Sarraj, 
1985a; Salole, Al-Sarraj, 1985b; Berbenni et al., 1999; 
Liebenberg et al., 2003).
Polymorphisms of pharmaceutical solids can modify 
their physicochemical properties (Vippagunta, Brittain, 
Grant, 2001; Grant, Byrn, 2004; Detoisien et al., 2011). 
When a pharmaceutical solid exists in more than one 
form or crystal structure, significant differences in drug 
solubility may be detected, particularly for drugs that 
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are poorly water-soluble and classified as class II and IV 
according to the BCS (FDA, 2007; Bonfilio et al., 2014). 
In these cases, the dissolution step is the limiting step for 
drug absorption, and the lack of bioequivalence among 
different formulations may be related to polymorphisms 
(Amidon et al., 1995; Bauer et al., 2001; Desiraju, 2008; 
Aaltonen et al., 2009; Babu, Nangia, 2011; Santos et al., 
2014; Atici, Karliga, 2015).
The aim of this study was to characterize the 
polymorphisms of different active pharmaceutical 
ingredients (APIs) of SPR obtained from different 
manufacturers. The effect of SPR crystal structure was 
also studied by performing physicochemical quality 
evaluations of tablets manufactured in our laboratory using 
API in pure form II, and API in form II contaminated with 
form I. Tablets commercially available in Brazil from 
different manufacturers were also evaluated.
MATERIAL AND METHODS
Samples, chemicals, and reagents
All reagents were of analytical grade, and were 
supplied by Núcleo de Controle de Qualidade da Faculdade 
de Ciências Farmacêuticas da Universidade Federal de 
Alfenas-MG (NCQ/FCF-UNIFAL-MG). The chemical 
reference substance (CRS) was a secondary standard 
validated in our laboratory, and designated as SPR-pd 2° 
NCQ (Assay of 102.4%, from Galena®, Campinas, São 
Paulo, Brazil). Five batches of APIs of SPR from three 
manufacturers were selected for analysis; these were 
designated as SPR-L1 to SPR-L5. The excipients (starch, 
microcrystalline cellulose, magnesium stearate, lactose 
hydrous, and colloidal silicon dioxide) were purchased 
from local drugstores.
Spironolactone tablets (50 mg) commercially 
available in Brazil from three manufacturers were also 
analyzed. The reference drug product in Brazil (Aldactone® 
50 mg manufactured by Pfizer™) was denominated as 
SPR-R. Three batches of tablets approved by the National 
Health Surveillance Agency (Anvisa) as generic equivalent 
products were analyzed, and they were designated as 
SPR-G1 (manufacturer 1), SPR-G2 (manufacturer 2), and 
SPR-G3 (manufacturer 3). A non-approved batch by Anvisa, 
as a generic equivalent product, and also commercialized 
by manufacturer 1, was also analyzed (SPR-S).
HPLC analysis
Samples of APIs and tablets were analyzed using an 
HPLC system from Shimadzu (Kyoto, Japan). Analyses 
were carried out using a validated method according to 
United States Pharmacopeia (USP, 2015), and used a 
C18 end-capping column [150.0 x 4.6 mm (i.d.)] with a 
5 µm particle size (Agilent Technologies®, Santa Clara, 
CA, USA) at 25°C. The mobile phase was a mixture of 
methanol and water (60:40, v/v). The flow rate of the 
mobile phase was 1.0 mL min-1, injection volume was 
50 µL, and UV detection was carried out at 230 nm. 
Standard solutions at different SPR concentrations (10, 20, 
40, 60, 80, 100 µg mL-1) were diluted in acetonitrile:water 
(1:1, v/v) and analyzed (n = 3). The calibration equation 
and correlation coefficient (r) were y = 46719x + 9188.3 
and 0.99975, respectively. The samples were filtered using 
a 0.45 µm syringe filter composed by hydrophilic PTFE. 
The retention time of SPR was approximately 9.7 min. 
The total run time was 12.0 min.
Characterization of APIs
Powder X-ray diffraction (PXRD)
Measurements of APIs by PXRD (PXRD, Ultima 
IV model, Rigaku®, Tokyo, Japan) were carried out 
at room temperature under the following conditions: 
graphite monochromated Cu-Kα radiation (λ = 1.54187 
Å), voltage of 40 kV, current of 30 mA, and rate scan of 
1°/min between 3 and 40° of the 2θ range. The analysis 
was performed in order to characterize crystal structures 
present in the APIs.
Thermal analysis
Differential scanning calorimetry (DSC) was 
performed using a Netzsch-Gerätebau GmbH instrument 
model DSC 3500 Sirius (Selb, Germany). DSC thermograms 
of SPR were obtained at a heating rate of 10 °C min−1, from 
30 °C to 240 °C, under a N2 purge of 50 mL min−1 (n = 3). 
Thermogravimetric analysis (TGA) was performed using an 
Exstar TG/DTA-7300 thermogravimetric analyzer (Chiba, 
Japan). TGA thermograms were obtained at a heating rate 
of 10 °C min−1, from 40 °C to 400 °C, under a N2 purge of 
50 mL min−1. 
FIGURE 1 - Chemical structure of spironolactone (C24H32O4S). 
Molecular weight: 416.58 g mol-1.
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Fourier transformed infrared spectroscopy with 
attenuated total reflection
Infrared analysis of the samples was performed using 
a Fourier transform infrared (FTIR) spectrometer, Shimadzu 
model Prestige 21 (Kyoto, Japan). An attenuated total 
reflectance (ATR) sampling accessory (model GladiATR 
300, Pike Technologies, USA) was used, and the spectra 
were collected with no further processing of the samples.
Solubility
Solubility measurements were performed by a 
shaking-flask method at 25 °C. An excess of API was 
added to each medium (5 mL) and shaken (150 rpm) for 
48 h (n = 3). The supernatant was taken, filtered using a 
0.45 µm syringe filter composed by hydrophilic PTFE, 
diluted in mobile phase (1:1, v/v), and analyzed by HPLC. 
The following media were evaluated: water; 
0.01 mol L-1 chloride acid (HCl); 0.1 mol L-1 HCl; 
0.1 mol L-1 HCl + 0.1% (w/v) sodium dodecyl sulfate; 
0.1 mol L-1 sodium citrate buffer (pH 3.0); 0.1 mol L-1 
sodium acetate buffer (pH 4.5); 0.1 mol L-1 potassium 
phosphate buffer (pH 6.2); and 0.1 mol L-1 potassium 
phosphate buffer (pH 7.2).
Preparation of SPR tablets
To evaluate the influence of polymorphisms 
in spironolactone tablets (50 mg), two batches were 
prepared; batch A (containing SPR-L1 in polymorphic 
form II, but with contamination by polymorphic form I) 
and batch B (containing SPR-L2 in polymorphic form 
II without contamination). The particles of SPR APIs 
were previously sieved (48–60 µm). The two batches 
were prepared in a similar manner by direct compression 
using a single rotary tablet compression machine. A 
placebo mixture was prepared based on the qualitative 
composition of reference drug product by weighing out 
the following ingredients: starch (6.5%), microcrystalline 
cellulose (77.0%), magnesium stearate (1.0%), lactose 
hydrous (15%), and colloidal silicon dioxide (0.5%). 
These excipients were mixed with API (batch A or batch 
B), and the mixture was compressed. The average weight 
(±relative standard deviation, RSD) and hardness of the 
manufactured SPR tablets were adjusted according to the 
data obtained from physical tests with the SPR-R.
Physicochemical quality evaluation of APIs and 
tablets
Assay
Assays of APIs and tablets were performed according 
to the specifications of USP (2015). Samples were diluted 
in mobile phase at a drug concentration of 40.0 μg mL-1 (n 
= 5), and analyzed by HPLC.
Content uniformity of the manufactured SPR tablets
Evaluation of the homogeneity of the manufactured 
tablets (batch A and batch B) was performed according to 
the specifications of USP 38-NF 33 (2015). Samples at a 
final concentration of 50.0 μg mL-1 diluted in mobile phase 
were prepared (n = 10) and analyzed by HPLC.
Evaluation of the dissolution profiles
Evaluation of the dissolution profiles of the tablets (n 
= 6) was performed in a ElectrolabTM TDT-08 L multi bath (n 
= 8) dissolution test system (Mumbai, Maharashtra, India). 
The following conditions were used: USP II apparatus 
(paddle) at 75 rpm and 1000 mL of 0.1 mol L-1 HCl + 
0.1% sodium dodecyl sulfate at 37.0 ± 0.5 °C. Samples 
were withdrawn (10 mL) at different times (5, 10, 15, 
30, 45, 60, and 90 min), filtered using quantitative paper 
filter, and diluted with dissolution medium (1:1, v/v). The 
quantification of SPR in dissolution medium was performed 
by UV spectrophotometry (λ = 242 nm) using a Shimadzu® 
spectrophotometer, model UV-1800 PC (Kyoto, Japan). 
The dissolution profiles of the SPR tablets marketed 
in Brazil were compared by calculating the dissolution 
efficacy (DE0-90%) as the percentage of the area under the 
release curve between 0 and 90 min (Anderson et al., 1998; 
Serra, Storpirtis, 2007).
The dissolution profiles of tablets manufactured 
in our laboratory, batch A and batch B, were compared 
using the model-independent mathematical approach by 
calculating the factor f2: 
where, n is the number of selected time points; Rt is the 
cumulative percentage dissolved at each of the selected 
n time points of the reference product; and Tt is the 
cumulative percentage dissolved at each of the selected 
n time points of the test product. The factor f2 measures 
the closeness between the two dissolution profiles, and a 
value between 50 and 100 indicates similarity of the two 
profiles (Farmacopeia, 2010; FDA, 2014). 
Statistical analysis
Samples were compared using 1-way analysis of 
variance (ANOVA). In all cases, post hoc comparisons 
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of the means for individual groups were performed 
using Tukey’s test. P values of <0.05 were considered 
statistically significant.
RESULTS AND DISCUSSION
Characterization of active pharmaceutical 
ingredients
The identification of crystal structures in APIs in the 
solid state was determined using PXRD. The diffraction 
pattern is related to the packing of the crystal structure 
and its array in the solid state (Bonfilio et al., 2014). To 
determine the occurrence of polymorphisms in APIs of 
SPR, diffractograms (SPR-L1 to L5, and SPR-pd2º NCQ) 
were compared to data available from the Cambridge 
Structural Database (CSD) for crystal form I (Dideberg; 
Dupont, 1972) and crystal form II (Agafonov, Legendre, 
Rodier, 1989). These data are shown in Figure 2A.
These results indicate the occurrence of pure form II 
in samples SPR-L2, SPR-L3, SPR-L4, SPR-L5, and SPR-R 
(Figure 2B). Peaks at 10.1, 13.2, 14.6, and 15.2 °2θ were 
observed in SPR-L1, and related to a contamination with form 
I, characterizing this API as a mixture of both forms I and II. 
Similar results were observed by Liebenberg and coworkers 
(2003) during the evaluation of five different SPR APIs using 
PXRD, in which they characterized one batch of API as a 
mixture of crystal forms I and II. In general, SPR is used in the 
pharmaceutical industry in form II due to its higher stability 
(Nicolai et al., 2007; Zhang et al., 2014). However, these 
results indicate that SPR APIs from different manufacturers 
may be contaminated with other crystal structures, leading 
to problems in formulation performance. 
The characterization of the APIs SPR-pd 2º NCQ 
(pure form II), SPR-L1 (pure form II), and SPR-L2 (form II 
contaminated with form I) was also performed by thermal 
analysis (DSC and TGA) in order to determine melting 
point and thermal stability. The melting point of SPR-pd 
2° NCQ (Figure 3A) was 209.1°C (Tonset = 203.0 °C), and 
drug decomposition from 250 °C. These results are similar 
to those described for crystal form II (Agafonov et al., 
1991; Espeau et al., 2007).
DSC thermograms of SPR-L1 and SPR-L2 (Figure 
3B) showed melting points of 207.0 °C (m = 5.62 mg/
DPR: 0.05%/Tonset: 197.3 °C/ΔHfus = 43.6 mJ mg-1) and 
209.2 °C (m = 5.63 mg/DPR: 0.09%/Tonset: 202.7 °C/
ΔHfus = 45.2 mJ mg-1), respectively. These results are 
similar those described by Liebenberg and coworkers 
(2003), in which the melting point of SPR API in pure 
form II (204 °C) was slightly lower compared to form II 
contaminated with form I (205–206 °C). Form II has a 
higher thermodynamic stability than form I, observed by 
its enthalpy of fusion (Agafonov et al., 1989; Agafonov 
et al., 1991; Liebenberg et al., 2003, Espeau et al., 2007). 
Drug decomposition was observed from 250 °C by TGA 
thermograms (Figure 3C).
Infrared spectra of the APIs (SPR-pd2º NCQ, 
SPR-L1, and SPR-L2) are shown in Figure 4. Stretching 
vibrations of thioacetyl were observed at 1689 cm-1, with 
stretching of γ-lactone at 1766 cm-1. Carbonyl (C=O) 
stretching at 1668 cm-1 and the stretching vibration of the 
C=C bond at 1615 cm-1 were also observed. Differences 
among the infrared spectra of the evaluated SPR APIs 
were not observed. According to Berbenni and coworkers 
(1999), the discrimination of SPR polymorphs using 
infrared spectroscopy is not a simple task, and PXRD is 
recommended for appropriate characterization of SPR 
crystal forms. 
FIGURE 2 - PXPD of spironolactone in active pharmaceutical ingredients: A) SPR-L1 to SPR-L5 in comparison with the simulated 
PXPD of forms I and II; B) Characterization of form II contaminated with form I in SPR-L1.
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Assays of the APIs in SPR showed values of 
99.90 ± 0.43% for SPR-L1, and 99.30 ± 0.89% for 
SPR-L2, according to the specifications in the API 
monograph (USP, 2015).
The solubility of SPR (Figure 5) form II was greater 
than that of form II contaminated with form I; this difference 
was seen in all aqueous media evaluated (p < 0.001). SPR 
solubility in 0.1 mol L-1 HCl + 0.1% (w/v) sodium dodecyl 
sulfate was increased approximately 3-fold compared to 
other aqueous media. The major difference between the 
solubility of SPR-L1 (150.74 ± 3.78 µg mL-1) and SPR-L2 
(101.10 ± 5.20 µg mL-1) was observed in this medium 
(p < 0.01), confirming that SPR solubility in form II may 
be increased due to contamination by form I. The medium 
0.1 mol L-1 HCl + 0.1% (w/v) sodium dodecyl sulfate is 
recommended by USP (2015) to perform the dissolution 
test of SPR tablets. Sodium dodecyl sulfate is an anionic 
surfactant that improves the solubility of poorly water-
soluble drugs due to the formation of a micellar solution 
(Ruela, De Araújo, Pereira, 2009). These results indicate 
that the in vivo performance of solid-state formulations 
containing different crystal structures of SPR may be 
modified, given that SPR is a poorly water-soluble drug 
and its dissolution is the limiting step for gastrointestinal 
absorption.
Evaluation of spironolactone tablets
The average weight of SPR tablets manufactured 
FIGURE 3 - A) DSC and TGA thermograms for the secondary 
reference standard (SPR-pd2º NCQ) of spironolactone in 
pure crystal form II; B) DSC and TGA thermograms of active 
pharmaceutical ingredients of spironolactone, SPR-L1 and 
SPR-L2, at a heating rate of 10 °C min-1.
FIGURE 4 - Infrared spectra of active pharmaceutical ingredients 
(APIs) of spironolactone: Secondary reference standard (SPR-pd 
2° NCQ), and two different APIs (SPR-L1 and SPR-L2).
FIGURE 5 - Solubility of spironolactone (n = 3) at 25 °C in 
aqueous media. The active pharmaceutical ingredients evaluated 
were SPR-L1, containing the crystal form II contaminated with 
form I, and SPR-L2, containing the pure form II.
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in our laboratory was 413.2 mg (RSD = 0.23%) for batch 
A, and 409.5 mg (RSD = 0.20%) for batch B. These 
results are close to the average weight of the reference 
drug product (409.2 mg, RSD = 1.90%). The hardness 
of the SPR tablets was 11.4 kgf for batch A, and 11.8 kgf 
for batch B, which is consistent with the hardness of the 
reference drug product (12.3 kgf). The content uniformity 
of the tablets were also determined (n = 10); results were 
100.97 ± 3.83% for SPR-R, 99.68 ± 2.12% for batch A, 
and 99.39 ± 0.83% for batch B.
Dissolution profiles of manufactured 
spironolactone tablets
The dissolution profiles of tablets from batch A 
and B are shown in Figure 6A. The amount of drug 
dissolved at 60 min was 89.32 ± 3.43% for batch A, and 
79.55 ± 9.72% for batch B. However, comparison of 
the dissolution profiles using factor f2 indicates a value 
of 19.00. According to this result, dissolution profiles 
of the manufactured tablets were different, which may 
be related to the solubility of the APIs (SPR-L1 and 
SPR-L2). The dissolution rate of tablets in batch A was 
higher than those in batch B, and may be due to the fact 
that tablets in batch A were manufactured with a more 
soluble API (SPR-L1). Considering that, these solid-state 
formulations were prepared with the same excipients 
and process, the effect of SPR polymorphisms in drug 
solubility and dissolution rates may alter the in vivo 
pharmacokinetics of this drug, resulting in a lack of 
bioequivalence among drug products.
Dissolution profiles of spironolactone tablets 
marketed in Brazil
The dissolution profiles of tablets commercially 
available in Brazil are shown in Figure 6B. SPR-R tablet 
was characterized as a rapidly dissolving drug product, 
given that 84.86 ± 4.15% of the drug was released at 5 
min. SPR-G2 and SPR-S tablets released more than 90% 
of the drug at 15 min, and they were also characterized as 
rapidly dissolving drug products. The same manufacturer 
produces SPR-G2 and SPR-S drug products. SPR-G1 
and SPR-G3 showed a slower dissolution rate than the 
other marketed drug products, achieving a dissolved 
drug amount >75% at 30 min. These results met the 
requirements of the monograph described by USP 38-NF 
33 (2015) for SPR tablets (dissolution >75% in 60 min). 
However, these results clearly demonstrate the lack of 
pharmaceutical equivalence among some formulations. 
The factor f2 was not applied for comparison of the 
dissolution profiles due to the fast release from the 
reference drug product, SPR-R (FDA, 2014). In this 
case, the DE0-90% was calculated to compare dissolution 
profiles (Figure 7).
There were significant differences among the values 
of DE0-90% for the marketed SPR tablets (p < 0.001). The 
DE0-90% of the reference drug product (SPR-R) showed 
the highest value (95.95 ± 1.32%), characterizing the 
rapid and complete release of SPR in a short time. The 
other marketed drug products did not achieve the same 
DE0-90% as SPR-R. SPR-G1 and SPR-G3 showed the 
lowest values of DE0-90% at 77.38 ± 3.24% and 73.24 ± 
3.53%, respectively, and they were significantly different 
from SPR-G2 and SPR-S, which showed values of 89.52 
± 1.55% and 89.92 ± 3.02%, respectively. These results 
indicate the lack of pharmaceutical equivalence among the 
evaluated solid-state formulations. Therefore, formulation 
scientists must carefully explore the design of SPR 
formulations in order to optimize their performance, and 
improve pharmaceutical equivalence and bioequivalence 
among these drug products.
FIGURE 6 - A) Dissolution profiles of spironolactone tablets (50 mg) in batch A and batch B (n = 6); B) Dissolution profiles of 
spironolactone tablets (50 mg) marketed in Brazil (n = 6).
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CONCLUSIONS
The polymorphs of SPR in raw materials from 
different manufacturers were characterized as pure form 
II in four batches of this API, and one commercial batch 
containing form II contaminated with form I. The solubility 
measurements of these APIs indicated a higher solubility 
of form II contaminated with form I compared to the API in 
pure form II. Analysis of tablets manufactured with these 
APIs indicated that the presence of form I in the API leads 
to an increased dissolution rate, which was associated with 
the major solubility of this crystal structure. Different 
dissolution profiles were also characterized from SPR 
tablets marketed in Brazil, suggesting that formulation 
composition may modify the release rate of this poorly 
water-soluble drug. Collectively, these findings indicate 
the need for preformulation studies to characterize the 
polymorphs of SPR in APIs. In addition, formulation 
scientists must consider the impact of polymorphs in solid-
state formulations, as well as that of the excipients, on the 
dissolution properties of these formulations.
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